ACADIA Pharmaceuticals Inc.

Company Overview

Acadia Pharmaceutical is a biopharmaceutical company located in San Diego, Calif., that engages in the development and manufacturing of drugs for central nervous system (CNS) disorder disease.

Acadia’s key drug includes Nuplazid (pimavanserin), intended to treat the patients of delusions and hallucinations associated with Parkinson’s disease psychosis (PD psychosis). This drug is only approved in the U.S. The company pipeline includes creative products in the central nervous system (CNS) area, such as Trofinetide drug for the treatment of Rett Syndrome disease, Pimavanserin for the treatment of major depression disorder disease and schizophrenia disease, and Nuplazid for the treatment of Parkinson’s disease.

Acadia has an exclusive license to manufacture and produce the Trofinetide drug in North America from Neuren Pharmaceutical. The company is leading a Phase II preliminary clinical study, referred to as the SERENE Study, intended to inspect the safety and efficiency of pimavanserin as a treatment for Alzheimer’s infection (AD) agitation. The company also studies the use of pimavanserin drug in patients who suffer from schizophrenia and major depressive disorder who have an insufficient reaction to standard antidepressant therapy with both a particular serotonin norepinephrine reuptake inhibitor (SNRI) and serotonin reuptake inhibitor (SSRI).

On Jan. 10, 2022, the company collaborated with Stoke Therapeutics Inc to discover, manufacture and market novel RNA-based medicines that can be used for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.

Financial Highlights (FY 2024)

Company's Business Segments

• NUPLAZID : NUPLAZID also known as Pimavanserin is the only FDA-approved treatment for Hallucinations, Delusions associated with Parkinson’s Disease Psychosis.
• DAYBUE : DAYBUE also known as Trofinetide is the only FDA-approved treatment for Rett Syndrome.